Not adjusting for serum vitamin D levels might lead to an overestimation of the effect when GLP-1 RA users have lower serum vitamin D levels as compared to the users of other anti-hyperglycemic drugs. This evidence concerns the gene GLP1R and rheumatoid arthritis.